SG10202110563YA - Ganaxolone for use in treating genetic epileptic disoders - Google Patents
Ganaxolone for use in treating genetic epileptic disodersInfo
- Publication number
- SG10202110563YA SG10202110563YA SG10202110563YA SG10202110563YA SG10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA
- Authority
- SG
- Singapore
- Prior art keywords
- disoders
- ganaxolone
- treating genetic
- epileptic
- genetic epileptic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584403P | 2017-11-10 | 2017-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202110563YA true SG10202110563YA (en) | 2021-11-29 |
Family
ID=66438123
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004329TA SG11202004329TA (en) | 2017-11-10 | 2018-11-09 | Ganaxolone for use in treating genetic epileptic disoders |
| SG10202110563YA SG10202110563YA (en) | 2017-11-10 | 2018-11-09 | Ganaxolone for use in treating genetic epileptic disoders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004329TA SG11202004329TA (en) | 2017-11-10 | 2018-11-09 | Ganaxolone for use in treating genetic epileptic disoders |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190160078A1 (en) |
| EP (1) | EP3706755A4 (en) |
| JP (2) | JP7312169B2 (en) |
| KR (1) | KR20200085837A (en) |
| CN (1) | CN111565724A (en) |
| AU (1) | AU2018364659A1 (en) |
| CA (1) | CA3079259A1 (en) |
| EA (1) | EA202091144A1 (en) |
| SG (2) | SG11202004329TA (en) |
| WO (1) | WO2019094724A1 (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103958540B (en) | 2011-09-08 | 2017-12-05 | 萨奇治疗股份有限公司 | Neuroactive steroids, composition, and application thereof |
| IL298436B1 (en) | 2012-01-23 | 2024-03-01 | Sage Therapeutics Inc | Pharmaceutical compositions comprising allopregnanolone |
| SI3461834T1 (en) | 2013-03-13 | 2021-11-30 | Sage Therapeutics, Inc. | Neuroactive steroids |
| IL286794B2 (en) | 2013-04-17 | 2024-06-01 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| RS60420B1 (en) | 2013-04-17 | 2020-07-31 | Sage Therapeutics Inc | 19-nor neuroactive steroids for methods of treatment |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| RU2754534C2 (en) | 2013-07-19 | 2021-09-03 | Сейдж Терапьютикс, Инк. | Neuroactive steroids, compositions and their use |
| DK3488852T3 (en) | 2013-08-23 | 2021-02-01 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES |
| ES2970222T3 (en) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxysterols and procedures for their use |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016061537A1 (en) | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CN107404877A (en) | 2014-10-16 | 2017-11-28 | 萨奇治疗股份有限公司 | Target the composition and method of CNS obstacles |
| SI3224269T1 (en) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| PL3250210T3 (en) | 2015-01-26 | 2021-07-26 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JP6875996B2 (en) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | Neurostimulatory steroids, compositions, and their use |
| WO2017007840A1 (en) | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JP6882996B2 (en) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | Oxysterols and how to use them |
| CA2991214C (en) | 2015-07-06 | 2024-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| RU2022102537A (en) | 2016-03-08 | 2022-03-30 | Сейдж Терапьютикс, Инк. | NEUROACTIVE STEROIDS, THEIR COMPOSITIONS AND APPLICATIONS |
| PL3436022T3 (en) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3919502A1 (en) | 2016-07-07 | 2021-12-08 | Sage Therapeutics, Inc. | 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions |
| EP3481844B1 (en) | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| AU2017297375B2 (en) | 2016-07-11 | 2022-09-15 | Sage Therapeutics, Inc. | C17, C20, and C21 substituted neuroactive steroids and their methods of use |
| CN110088091A (en) | 2016-08-23 | 2019-08-02 | 萨奇治疗股份有限公司 | 19- removes the crystal of the disubstituted C21-N- pyrazolyl steroids of first C3,3- |
| MA46351A (en) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | C7 SUBSTITUTED OXYSTEROLS AND PROCESSES AS NMDA MODULATORS |
| MA46566A (en) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | OXYSTEROLS AND THEIR METHODS OF USE |
| WO2018075698A1 (en) | 2016-10-18 | 2018-04-26 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
| US20220023316A1 (en) * | 2018-12-14 | 2022-01-27 | Praxis Precision Medicines, Inc. | Methods for the treatment of depression |
| CN113272315B (en) * | 2018-12-26 | 2023-08-08 | 张家口华健致远生物科技有限公司 | Steroid compounds and application thereof |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| JP2022540253A (en) | 2019-07-11 | 2022-09-14 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Formulations of T-type calcium channel modulators and methods of use thereof |
| JP2022552808A (en) * | 2019-10-02 | 2022-12-20 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Combination of GABA-A Receptor Positive Allosteric Modulators and NMDA Antagonists, NMDA Negative Allosteric Modulators, or NMDA Partial Agonists |
| MX2022006014A (en) * | 2019-12-06 | 2022-06-22 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating tuberous sclerosis complex. |
| EP4142764A4 (en) * | 2020-04-29 | 2024-05-29 | Praxis Prec Medicines Inc | Methods of use of t-type calcium channel modulators |
| WO2022125408A1 (en) * | 2020-12-07 | 2022-06-16 | Marinus Pharmaceuticals, Inc | Use of ganaxolone in treating an epilepsy disorder |
| WO2023060024A1 (en) * | 2021-10-04 | 2023-04-13 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders |
| WO2023060067A1 (en) * | 2021-10-04 | 2023-04-13 | Marinus Pharmaceuticals, Inc. | Amorphous solid dispersion ganaxolone formulation |
| US20230321116A1 (en) * | 2022-02-16 | 2023-10-12 | Lipocine Inc. | 3Alpha-OH-5Beta-Pregnan-20-One Compositions and Methods for Treating Central Nervous System Disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5556847A (en) * | 1994-10-27 | 1996-09-17 | Duquesne University Of The Holy Ghost | Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors |
| US5888996A (en) * | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| IL298436B1 (en) * | 2012-01-23 | 2024-03-01 | Sage Therapeutics Inc | Pharmaceutical compositions comprising allopregnanolone |
| EP3957309A1 (en) | 2012-08-21 | 2022-02-23 | Sage Therapeutics, Inc. | Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin |
| US9629853B2 (en) * | 2014-05-21 | 2017-04-25 | Wisconsin Alumni Research Foundation | Uses of ganaxolone |
| CN107427458A (en) * | 2015-02-06 | 2017-12-01 | 马瑞纳斯制药公司 | Intravenous ganaxolone preparation and its purposes in treatment status epilepticus and other seizure disorders |
| CA3001722A1 (en) * | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| RU2022102537A (en) | 2016-03-08 | 2022-03-30 | Сейдж Терапьютикс, Инк. | NEUROACTIVE STEROIDS, THEIR COMPOSITIONS AND APPLICATIONS |
| KR102518846B1 (en) * | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | Methods and compositions for the treatment of epileptic disorders |
| CN110520131A (en) * | 2017-04-18 | 2019-11-29 | 马瑞纳斯制药公司 | The neurosteroid preparation of sustained release injectable |
-
2018
- 2018-11-09 SG SG11202004329TA patent/SG11202004329TA/en unknown
- 2018-11-09 CA CA3079259A patent/CA3079259A1/en active Pending
- 2018-11-09 WO PCT/US2018/060037 patent/WO2019094724A1/en unknown
- 2018-11-09 SG SG10202110563YA patent/SG10202110563YA/en unknown
- 2018-11-09 JP JP2020526304A patent/JP7312169B2/en active Active
- 2018-11-09 CN CN201880085880.3A patent/CN111565724A/en active Pending
- 2018-11-09 EA EA202091144A patent/EA202091144A1/en unknown
- 2018-11-09 KR KR1020207016409A patent/KR20200085837A/en not_active Application Discontinuation
- 2018-11-09 EP EP18876989.7A patent/EP3706755A4/en active Pending
- 2018-11-09 US US16/185,677 patent/US20190160078A1/en not_active Abandoned
- 2018-11-09 AU AU2018364659A patent/AU2018364659A1/en active Pending
-
2022
- 2022-03-24 US US17/703,331 patent/US20220249515A1/en not_active Abandoned
-
2023
- 2023-07-07 JP JP2023112339A patent/JP2023153783A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA202091144A1 (en) | 2020-09-16 |
| SG11202004329TA (en) | 2020-06-29 |
| JP2023153783A (en) | 2023-10-18 |
| JP7312169B2 (en) | 2023-07-20 |
| EP3706755A4 (en) | 2021-11-10 |
| KR20200085837A (en) | 2020-07-15 |
| CA3079259A1 (en) | 2019-05-16 |
| CN111565724A (en) | 2020-08-21 |
| WO2019094724A8 (en) | 2022-10-06 |
| EP3706755A1 (en) | 2020-09-16 |
| AU2018364659A1 (en) | 2020-05-28 |
| JP2021502403A (en) | 2021-01-28 |
| US20220249515A1 (en) | 2022-08-11 |
| WO2019094724A1 (en) | 2019-05-16 |
| US20190160078A1 (en) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202110563YA (en) | Ganaxolone for use in treating genetic epileptic disoders | |
| EP3364869C0 (en) | A system for treating a neural site in a body | |
| HK1245287A1 (en) | IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT | |
| HK1257490A1 (en) | Chimeric aav-anti-vegf for treating cancer in canines | |
| IL272596A (en) | Pridopidine for use in treating als | |
| SI3307296T1 (en) | Timp2 for use in treating aging-associated conditions | |
| IL264641A (en) | Acetyl-leucine for use in treating neurodegenerative diseases | |
| IL266530B1 (en) | Aramchol for use in fibrosis treatment | |
| IL272027B (en) | Endothal prodrugs for use in treating cancer | |
| PL3534885T3 (en) | Farnesyltransferase inhibitors for use in treating cancer | |
| HK1257935A1 (en) | Aminoglycoside derivatives and uses thereof in treating genetic disorders | |
| PL3197839T3 (en) | Method and arrangement for wastewater treatment | |
| FI3551189T3 (en) | Alprazolam for use in treating epilepsy | |
| IL262143A (en) | Improvements in cancer treatment | |
| ZA201802618B (en) | Anti-cd43 antibody and use thereof for cancer treatment | |
| LT3406258T (en) | Medicament for use in treating gout | |
| GB201615844D0 (en) | Agents for use in therapy | |
| GB201604658D0 (en) | Treatment for pain | |
| GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
| HRP20191908T1 (en) | Paroxysmal extreme pain disorder treatment | |
| GB201702652D0 (en) | Delta-theraphotoxin-Ac1 for use in treating diabetes | |
| GB201505205D0 (en) | Treatment for pain | |
| GB201504688D0 (en) | Treatment for pain |